Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We employ our advanced, specialised process to create targeted libraries for ion channels.
Fig. 1. The sreening workflow of Receptor.AI
This includes extensive molecular simulations of the ion channel in its native membrane environment, in open, closed, and inactivated forms, paired with ensemble virtual screening that factors in conformational mobility in each state. Tentative binding pockets are considered in the pore, the gating region, and allosteric areas to capture the full range of mechanisms of action.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q9NSA2
UPID:
KCND1_HUMAN
Alternative names:
Voltage-gated potassium channel subunit Kv4.1
Alternative UPACC:
Q9NSA2; A6NEF1; B2RCG0; O75671
Background:
Potassium voltage-gated channel subfamily D member 1, also known as Kv4.1, plays a crucial role in the electrical signaling of neurons and cardiac cells. It forms the pore-forming (alpha) subunit of voltage-gated rapidly inactivating A-type potassium channels, contributing to the I(To) current in the heart and I(Sa) current in neurons. Its activity is finely tuned through interactions with other alpha subunits and regulatory subunits.
Therapeutic significance:
Understanding the role of Potassium voltage-gated channel subfamily D member 1 could open doors to potential therapeutic strategies.